1	Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma
2 3	Samantha K Davis ¹ , Kevin John Selva ¹ , Ester Lopez ¹ , Ebene R Haycroft ¹ , Wen Shi Lee ^{1,2} , Adam
4	K Wheatley ¹ , Jennifer A Juno ¹ , Amy Adair ² , Phillip Pymm ² , Samuel J Redmond ¹ , Nicholas A
5	Gherardin ¹ , Dale I Godfrey ¹ , Wai-Hong Tham ² , Stephen J Kent ^{1,3*} , Amy W Chung ^{1*} .
6	
7	1 Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and
8	Immunity, University of Melbourne, Melbourne, Victoria
9	2 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
10	3 Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital
11	and Central Clinical School, Monash University, Melbourne, Victoria, Australia
12	
13 14 15 16 17	*Contributed equally, correspondence to: Amy Chung <u>awchung@unimelb.edu.au</u> or Stephen Kent <u>skent@unimelb.edu.au</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 Abstract

36

Following infection with SARS-CoV-2, virus-specific antibodies are generated which can both 19 neutralise virions and clear infection via Fc effector functions. The importance of IgG 20 21 antibodies for protection and control of SARS-CoV-2 has been extensively reported. In 22 comparison, other antibody isotypes including IgA have been poorly characterized. Here we 23 characterized plasma IgA from 41 early convalescent COVID-19 subjects for neutralisation and Fc effector functions. We find that convalescent plasma IgA from >60% of the cohort have the 24 25 capacity to inhibit the interaction between wild-type RBD and ACE2. Furthermore, a third of 26 the cohort induced stronger IgA-mediated inhibition of RBD binding to ACE2 than IgG, when 27 tested at equivalent concentrations. Plasma IgA and IgG from the cohort, broadly recognize 28 similar RBD epitopes and showed similar ability to inhibit ACE2 from binding 22 of 23 different 29 prevalent RBD proteins with single amino acid mutations. Plasma IgA was largely incapable of 30 mediating antibody-dependent phagocytosis in comparison to plasma IgG. Overall, 31 convalescent plasma IgA contributes to neutralisation towards wild-type RBD and various RBD 32 single mutants in most subjects, although this response is heterogeneous and less potent than 33 lgG. 34

35 Running Title: Heterologous SARS-CoV-2 IgA Neutralisation

37 Key Words: SARS-CoV2, IgA, Neutralisation, Fc function, RBD, ACE2 inhibition

Introduction 38

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of 39 40 Coronavirus disease 2019 (COVID-19) has infected millions of people and caused over 5.6 41 million deaths globally since its discovery. SARS-CoV-2 trimeric spike protein consists of two 42 domains; spike 1 (S1) and spike 2 (S2) (Wrapp et al., 2020). The receptor binding domain (RBD) 43 within the S1 engages with angiotensin-converting enzyme 2 (ACE2) on human cells 44 contributing to infection (Wrapp et al., 2020). Antibodies generated towards RBD following 45 infection or vaccination can block engagement with ACE2 and neutralise SARS-CoV-2 (Collier 46 et al., 2021; Lustig et al., 2021; Wheatley et al., 2021). Mutations within the RBD can generate 47 variants that have improved transmissibility and can lead to escape of antibody immunity 48 from vaccination or infection, thus potentially becoming variants of concern (VOC) (Dupont 49 et al., 2021; Falsey et al., 2021; Rössler et al., 2021). Importantly, both neutralising and nonneutralising antibodies engage fragment crystallisable (Fc) receptors on immune cells (e.g. 50 monocytes) to activate Fc effector functions to clear infection (Chan et al., 2021; Tauzin et al., 51 2021; Ullah et al., 2021; Winkler et al., 2021). This polyfunctional antibody response assists in 52 protection and control of viral infections, such a SARS-CoV-2 (Natarajan, Crowley, et al., 53 54 2021a; Sadarangani et al., 2021).

55

56 SARS-CoV-2 infection and vaccine-induced plasma antibodies directed towards RBD have been widely reported to neutralise SARS-CoV-2 using the fragment antigen binding (Fab) 57 portion (Devarasetti et al., 2021; Lopez et al., 2021; Wheatley et al., 2021). Convalescent 58 59 plasma IgG and IgM have been heavily studied, with both isotypes playing a large role in the neutralising response to SARS-COV-2 wild-type (WT) and VOC's (Gasser et al., 2021; Liu et al., 60 2020; Maeda et al., 2021). Limited studies suggest plasma IgA dominates neutralisation of 61 62 SARS-CoV-2 WT during early infection and decreases into convalescence (Klingler et al., 2020; 63 Sterlin et al., 2021). Importantly, some IgA monoclonal antibodies (mAb's) (monomeric and dimeric) can neutralise SARS-CoV-2 WT very effectively (Ejemel et al., 2020; Wang et al., 64 65 2021). The importance of plasma IgA induced by infection with SARS-CoV-2 WT and their 66 capacity to inhibit ACE2 binding to RBD mutants remains to be assessed.

67

Neutralising and non-neutralising antibodies, including IgG and IgA, can engage Fc receptors 68 69 (FcyR and Fc α R respectively) on immune cells and activate Fc effector functions to clear viral

70 infection (Asokan et al., 2020; Blutt et al., 2012; Davis et al., 2020). Effector functions including complement activation, phagocytosis, and antibody dependent cellular cytotoxicity (ADCC) 71 72 have been implicated in clearance and control of SARS-CoV-2 infection (Dufloo et al., 2021; 73 Lee et al., 2021; Natarajan et al., 2021). Importantly, compromised Fc effector function and 74 reduced neutralising potency have been linked to poorer disease outcomes in humans 75 (Garcia-Beltran et al., 2021; Zohar et al., 2020). The necessity for a polyfunctional IgG antibody 76 response has also been highlighted in animal models, where neutralising human IgG 77 monoclonal antibody (mAb) therapy protects from SARS-CoV-2 infection when given as a 78 prophylactic mAb but requires additional Fc functions for optimal protection when given as a 79 therapeutic (Chan et al., 2021; Winkler et al., 2021). However, the importance of plasma IgA 80 for optimal Fc effector function has yet to be characterised.

81

The functional capacity of polyclonal convalescent IgA to SARS-CoV-2 has yet to be characterised, especially to RBD mutations associated with VOC. Here we examined purified fractions of plasma and purified IgA and IgG, to investigate the contribution of these isotypes to the polyclonal convalescent antibody response to RBD and prevalent single amino acid RBD mutants.

87

88 Results

Robust antibody recognition and ACE2 binding inhibition by SARS-CoV-2 convalescent plasma

91 41 SARS-CoV-2 convalescent subjects (median age of 55; IQR 49-61) ~41 days post symptom 92 onset and 26 uninfected subjects (mean age of 54; IQR 24-60) donated plasma samples (sup. 93 table 1.). To determine Spike-1 (S1) and RBD wild-type (RBDWT) antibody binding, convalescent and uninfected subject plasma were assessed for IgM, IgG, and IgA binding using 94 95 a SARS-CoV-2 multiplex bead array (Selva et al., 2021b) (fig. 1, sup. fig. 1a-c). Most SARS-CoV-2 convalescent subjects generated IgM, IgG, and IgA antibodies to RBDWT (IgM: 73.15% 96 97 positive, median MFI=54086; IgG: 100% positive, median MFI=45745; IgA 97.56% positive, 98 median MFI=2495) (fig. 1a-c).

99

To examine the ability of subject plasma to neutralise SARS-CoV-2, we used a multiplex
 RBDWT-ACE2 binding inhibition assay, that has been demonstrated to highly correlate with

gold standard live microneutralization assays (Lopez et al., 2021). Almost all convalescent subjects (95.12%) generated significant inhibition of ACE2 binding to RBDWT (median=73.23%, with ACE2 binding inhibition <20% considered to be below the limit of dection (Lopez et al., 2021)) (fig. 1d). Significant S1-ACE2 binding inhibition was also observed for convalescent subject plasma compared to uninfected subjects (sup. fig. 1d & e). Thus, most SARS-CoV-2 convalescent plasma induced antibodies that recognise RBDWT and have the capacity to inhibit the binding of RBD to ACE2, as previously reported (Lopez et al., 2021).

110 RBDWT antibody isotype titres (IgG, IgM and IgA) have previously been correlated to the level 111 of plasma neutralisation or ACE2 binding inhibition (Gasser et al., 2021; Lopez et al., 2021; 112 Sterlin et al., 2021). Here the cohort was broken down by isotype seropositivity and the ability to block ACE2 engagement with RBDWT to observe the surface level contribution of the 113 isotypes to neutralisation in this cohort (fig. 1e). The majority (68.29%, 28 out of 41) of the 114 115 convalescent cohort were seropositive for all 3 isotypes (RBDWT IgM, IgG and IgA) with 100% (28 out of 28) of these individuals being positive for ACE2 binding inhibition (fig. 1e). 29.27% 116 (12 out of 41) of the cohort were seronegative for IgM but seropositive for IgG and IgA, with 117 118 83.33% (10 out of 12) of these individuals being positive for ACE2 binding inhibition (fig. 1e). 119 A single individual (2.44% of the cohort) was seronegative for IgA but seropositive for IgM and 120 IgG and could mediate ACE2 binding inhibition (fig. 1e). To investigate the combined contribution of anti-RBDWT antibody isotypes (IgG, IgM and IgA) to ACE2 binding inhibition, 121 we performed partial least squares regression (PLSR) (fig. 1f-g). Not surprisingly, plasma 122 samples with the highest ACE2 inhibition (yellow – highest, dark blue weakest ACE2 inhibition) 123 predominantly cluster together across Latent Variable 1 (X- axis fig. 1f) and were strongly 124 associated with anti-RBDWT antibody isotype titres, with IgG and IgM being the strongest 125 126 correlates (fig. 1g). This was further confirmed by individual correlations with anti-RBDWT 127 antibody isotypes (sup. fig. 2). Similar trends were observed for S1 (sup. fig. 1a-e). This data highlights that robust anti-RBDWT IgM, IgG and IgA response develops against SARS-CoV-2 128 129 and persist during early convalescence.

130

IgA and IgG antibody depletion from convalescent plasma reduces ACE2 binding inhibition
IgG has been shown to play a critical role in plasma neutralisation to various viral infections,
including SARS-CoV-2 (W. T. Lee et al., 2021; Lopez et al., 2021; Maeda et al., 2021). However,

134 the contribution of plasma IgA to the convalescent SARS-CoV-2 neutralising antibody response, especially to emerging RBD mutants remains unclear (Sterlin et al., 2021; Verkerke 135 136 et al., 2021; Wang et al., 2021). To define the contribution of IgG and IgA to the neutralising 137 capacity of convalescent plasma, we depleted IgA from plasma (IgA- plasma) and also 138 depleted plasma of both IgA and IgG (IgA- and IgG- depleted plasma) to assess the capacity 139 of antibody depleted plasma fractions to inhibit RBDWT binding to ACE2 (fig. 2, sup. fig. 3). 140 Successful IgG and IgA depletion was confirmed by a significant reduction in IgA and IgG 141 binding to RBDWT (p<0.0001) and S1 (p<0.0001) for IgA- and IgA-/IgG- plasma (sup. fig. 3f-g, 142 i-j). 73.2% (30 out of 41) of convalescent IgA- plasma samples were successfully depleted of 143 IgA and had <30% loss of IgG or IgM (sup. fig. 3b).

144

145 ACE2 binding inhibition of whole plasma at 1:100 was compared to matched dilutions of IgA-146 and IgA-/IgG- plasma to investigate the contribution of IgA and IgG to convalescent plasma 147 neutralisation (fig. 2). IgA depletion reduced the capacity for convalescent plasma to mediate RBDWT-ACE2 binding inhibition by 22.14% (IgA depletion: median ACE2 inhibition=41.24%, 148 149 IQR 19.19%-65.41%,) compared to matched complete convalescent plasma (median ACE2 inhibition=63.38%, IQR 35.03%-75.92%, p=0.0001) (fig. 2a). We also investigated the 150 151 contribution of IgG to convalescent plasma neutralisation. IgG depletion (IgA-/IgG- plasma) 152 further reduced RBDWT-ACE2 binding inhibition by 15.68% (median ACE2 inhibition= 25.56%, IQR 14.64%-33.96%, p=0.08) compared to IgA- plasma (fig. 2a). Similar trends were observed 153 154 for S1 (sup. fig. 1f-h). This data suggests both IgA and IgG contributes to the neutralising 155 capacity of convalescent plasma for most individuals in this cohort.

156

157 The contribution of convalescent purified IgA to RBDWT-ACE2 binding inhibition is 158 heterogenous

Although the above depletion studies suggest IgA contributes to convalescent plasma neutralisation in the majority of the cohort, a more definitive role of IgA or IgG in neutralisation could be revealed by specifically purifying these fractions and measuring antibody binding using a multiplex bead array. First, we investigated the capacity for purified IgG and IgA to mediate ACE2 binding inhibition to RBDWT at 100µg/ml total antibody. Purified convalescent IgG (median=27.01% IQR 13-37%-41.87%) and IgA (median=12.17% IQR 0-31.39) mediated increased RBDWT-ACE2 binding inhibition compared to purified IgA

(median=12.57% IQR=5.633%-13.22%) and IgG (median=21.69% IQR=14.60-29.01) from uninfected donors, although this increase was not significant (IgA p=0.7810; IgG p=0.5665) (sup. fig. 4a-h). Not surprisingly a smaller proportion of individuals had detectable neutralization levels (>20% ACE2 inhibition; Purified IgA: 26.5% and Purified IgG: 59.18% of individuals, sup. fig 4c, f-h), than predicted by the IgA/IgG depletion experiments, likely due to the low concentration of purified IgA (100µg/ml) antibody available for use in these assays.

172

173 We next compared the ACE2 inhibitory capacity of matched purified IgG and IgA from the 174 same individuals at equivalent total purified antibody concentrations (100µg/ml). Overall, 175 within this cohort IgG mediated significantly higher ACE2 binding inhibition compared to IgA 176 (p=0.0045) (sup. fig. 4h). However, examining this cohort in greater detail, while 69.39% (34 177 out of 49) individuals had lower IgA mediated ACE2 binding inhibition (fig. 2b, sup. fig 4h), 178 interestingly, 30.1% (15 out of 49) of individuals mediated stronger ACE2 binding inhibition 179 via IgA instead of IgG (fig. 2c). Furthermore, the top 3 purified IgA neutralisers had comparable IgA mediated neutralisation when compared to the top 3 purified IgG neutralisers 180 181 (fig. 2b & c). Similar trends were observed for S1 antibody binding and ACE2 binding inhibition for purified convalescent IgG and IgA (sup. fig. 4a-c). We also demonstrate that the level of 182 183 RBD-specific antibody binding correlated with ACE2 binding inhibition for both purified IgA 184 (r=0.61, p<0.0001) and IgG (r=0.84, p<0.0001) (fig. 2d), suggesting that both IgG and IgA have the potential to neutralise SARS-CoV-2, however this is largely dependent on anti-RBDWT 185 antibody titre/ concentration. 186

187

188 To confirm the importance of antibody titre for an individual's ability to facilitate IgA 189 mediated ACE2 binding inhibition, increasing concentrations of purified IgA (12.5, 50 and 190 100µg/ml total antibody) were spiked back into IgA- plasma from individuals with IgA mediated ACE2 binding inhibition (>20%) where sufficient sample was available (n=3) (fig. 2e). 191 192 RBDWT-ACE2 binding inhibition of IgA- plasma increased with increasing concentrations of IgA, with a 2.98-fold increase in RBDWT-ACE2 binding inhibition compared to IgA- plasma 193 194 (median ACE2 inhibition=26.43% IQR=14.98%-35.50%) with addition of 100µg/ml purified IgA 195 (median ACE2 inhibition=40.61% IQR=34.05%-67.55%) (fig. 2f).

196

7

197 Intriguingly, upon further examination, we identified a small subset of individuals (n=3), where depletion of IgA resulted in a small increase in ACE2 inhibition (fig. 2g) (plasma: median 198 199 ACE2 inhbition= 54.41%, IgA depleted plasma: median ACE2 inhbition= 59.41%). We selected 200 the individual with the strongest level of RBDWT-ACE2 binding inhibition (CP30), and purified 201 IgA was spiked back into IgA depleted plasma at increasing concentrations for this individual. 202 IgM binding decreased (0.2-fold reduction, fig. 2h), whereas RBDWT-ACE2 binding inhibition 203 (0.5-fold increase, fig. 2i) surprisingly increased by the addition of $100\mu g/ml$ purified IgA. 204 These results demonstrate that in rare individuals, at higher titers, IgA may be able to block 205 RBD-specific IgM/IgG from binding, thus inhibiting ACE2 inhibition by other isotypes. This 206 inhibition is likely through IgA binding to non-neutralising epitope(s), thus blocking the 207 binding of other neutralising antibodies isotypes.

208

Antibody binding profiles of SARS-CoV-2 convalescent purified IgG and IgA to RBD single mutants

SARS-CoV-2 variants are rapidly emerging, that include amino acid mutations within the RBD, 211 212 some of which confer increased ACE2 affinity and antibody escape (Harvey et al., 2021; Verma & Subbarao, 2021). The capacity for IgG mAbs, convalescent plasma and plasma IgG to 213 214 recognise different RBD mutations has been widely characterised, however, the capacity of 215 convalescent purified IgA to recognise different RBD mutations is yet to be reported (Lopez et al., 2021; Maeda et al., 2021). To explore the impact of RBD mutations on IgA and IgG 216 driven ACE2 binding inhibition, plasma, IgA- depleted plasma and IgA-/IgG- depleted plasma 217 218 were assessed for ACE2 binding inhibition to a panel of 23 RBD single amino acid mutants, using a previously published competitive RBD-ACE2 inhibition multiplex assay (Lopez et al., 219 220 2021). As expected, weaker whole plasma ACE2 inhibition was observed for a number of RBD 221 single amino acid mutations including E484K (present in Beta and Gamma VOC) and N501Y 222 (present in Beta, Gamma and Omicron) as compared to RBD-WT, as previously described (Lopez et al., 2021). Depletion of IgA and IgG also reduced RBD-ACE2 inhibition levels across 223 224 all RBD variants, suggesting that IgA and IgG contribute to the recognition of RBD variants (fig. 225 3a, sup. fig. 5a).

226

To further characterise the IgA and IgG-driven ACE2 binding inhibition to RBD mutations,
 individuals who mediated stronger IgA-mediated RBDWT-ACE2 binding inhibition (median:

229 28.31%, n=13) were characterised further for their matched purified IgG and IgA binding and ACE2 binding inhibition to 23 RBD single amino acid mutations (fig. 3b-e). First, antibody 230 231 binding relative to RBDWT for 23 RBD single mutants was calculated using EC₅₀ values 232 obtained from the normalised antibody binding MFI for matched convalescent purified IgA 233 and IgG samples (titrations up to 100µg/ml) (fig. 3b & d, sup. fig. 5b). Importantly, for 18 of 234 the 23 mutants (78.26%) there was no significant difference in antibody binding for purified 235 IgG and IgA (fig. 3b & d). Overall, IgG trended towards better antibody binding (lower EC_{50}) 236 compared to IgA, with 5 RBD mutants (L455F (p= 0.0153), N439K (p=0.0153), T478I 237 (p=0.0107), K444R (p=0.0056) and V483F (p=0.032), all p-values adjusted for multiple 238 comparison) having significantly greater IgG recognition compared to IgA using multiple 239 comparisons (fig. 3b & d). Interestingly, the RBD mutant G446V showed a trend towards (adjusted p=0.0956) better IgA recognition relative to RBDWT (median EC₅₀=157.7 IQR=68.86-240 241 180.9) compared to IgG (median EC₅₀=246.5 IQR=108.9-400) (fig. 3b & d, sup. fig. 5b). Notably, 242 we observed a larger range in fold change for individual IgA binding (median range of fold change across all variants=7.017) relative to RBDWT for the 23 RBD mutants compared to IgG 243 244 (median range of fold change across all variants=0.64) (fig. 3b). This data suggests IgG and IgA 245 can recognise RBD mutations similarly.

246

247 We next investigated if differences in antibody recognition by IgG and IgA translated to a difference in ACE2 binding inhibition. We assessed the ACE2 binding inhibition capacity of 248 purified IgA and IgG for the same IgA neutralisers (n=13) to 23 RBD single mutants at a single 249 250 concentration (100µg/ml total antibody) using the previously described multiplex ACE2-251 inhibition array (fig. 3c & e). Purified IgG had significantly increased ACE2 binding inhibition relative to RBDWT compared to purified IgA for 1 RBD mutation (G476S) (p=0.011) (fig. 3c). 252 253 Purified IgG had enhanced recognition of G476S compared to purified IgA (not significant), 254 which may suggest that IgG and IgA may recognize different epitopes for this mutant (fig. 3b, 255 sup. fig. 5c). Importantly, for 22 of the 23 mutants (95.65%) there were marginal differences in ACE2 binding inhibition for purified IgG and IgA, suggesting that IgG and IgA can neutralise 256 257 most RBD mutants similarly. Taken together, this data suggests that purified convalescent IgA 258 and IgG have similar capacities to recognise most RBD mutations assayed here. Where significant differences were observed in IgG and IgA antibody recognition, ACE2 binding 259 260 inhibition or neutralisation was marginally impacted.

261

SARS-CoV-2 specific IgG mediates Fc effector function of convalescent plasma 262

Antibody Fc portions can engage with FcyR on monocytes to mediate antibody dependent 263 264 phagocytosis (ADP). Anti-SARS-CoV-2 IgG mAb's and plasma IgG has been reported to induce 265 robust ADCP responses, however, the Fc functional role of plasma IgA in SARS-CoV-2 is yet to 266 be characterised. Here, we investigated the capacity of convalescent plasma to induce ADP 267 using a previously described SARS-CoV-2 ADP bead assay (W. S. Lee et al., 2021). We 268 measured the antibody-mediated uptake of spike trimer (S)-conjugated fluorescent beads by 269 THP-1 monocytes with a subset of convalescent (n=18) and uninfected control plasma (n=12) 270 (fig. 4a). All convalescent subjects had higher ADP (median phagocytic score=9.31 x 10³ IQR= 271 7.14 x $10^3 - 11.20 \times 10^3$), compared to uninfected subjects (median phagocytic score=0.11 X 10^3 IQR=0 x 10^3 -0.45 x 10^3 , p<0.0001) (fig. 4a). To determine the contribution of IgA and IgG 272 273 to the ADP response against SARS-CoV-2, we measured ADP activity mediated by IgA- and 274 IgA-/IgG- plasma. (fig. 4b). Depletion of IgA had no effect on the ADP capacity of the convalescent plasma (convalescent plasma: median phagocytic score=9.31 x 10³; IgA- plasma: 275 median phagocytic score=10.01 x 10³ IQR= 5.91 x 10³ -12.98 x 10³, p>0.999) (fig. 4b). 276 Conversely, depletion of IgG (IgA-/IgG- plasma) (median=2.20 x 10³ IQR= 1.36 x 10³ -3.11 x 277 278 10³) resulted in a median loss of 76.37% ADP activity compared to convalescent plasma 279 (p<0.0001) (fig. 4b). This data highlights the importance of the IgG antibody isotype in the Fc 280 functional capacity of SARS-CoV-2 convalescent plasma.

281

282 In addition to uptake of antibody opsonised virions, antibodies can also mediate cell 283 association and trogocytosis of infected cells expressing SARS-CoV-2 spike. Using an established cell association assay (W. S. Lee et al., 2021), we measured antibody mediated 284 285 association of THP-1 monocytes with cells expressing SARS-CoV-2 spike (Ramos S-orange 286 cells) following incubation with convalescent (n=18) and uninfected subject plasma (n=12)287 (fig.4c). Antibody mediated association was detected in all convalescent subjects (median 288 association=15.04% association IQR= 6.63%-27.66%) when compared to uninfected subjects 289 (median association=0.3% association IQR= 0.08%-0.53%, p<0.0001) (fig. 4c). We then 290 investigated the contribution of IgA and IgG to cell association/ trogocytosis through depletion of IgA (IgA- plasma) and IgG (IgA-/IgG- depleted plasma) from convalescent plasma 291 292 (fig. 4d). Depletion of IgA (median association=10.02% IQR=6.50%-18.83%) did not significantly alter the cell association mediated by convalescent plasma (median association=15.04% association IQR= 6.63%-27.66%, p>0.99) (fig.4d). However, depletion of IgG (IgA-/IgG- plasma) (median association=1.33% association IQR=0.61%-3.10%) resulted in a median loss of 90.53% cell association relative to convalescent plasma (median association=15.04% association IQR= 6.63%-27.66%, p<0.0001) (fig. 4d). This data further supports the role of IgG convalescent plasma for an effective Fc functional response to SARS-CoV-2.

300

301 Discussion

302 A strong correlate of protection for most viral vaccines, including SARS-CoV-2 vaccines, are 303 neutralising antibodies (Khoury et al., 2021; Plotkin, 2010). IgM and IgG have been widely 304 implicated in effective neutralisation of SARS-CoV-2 (Gasser et al., 2021; Lopez et al., 2021; Natarajan, Xu, et al., 2021; Wheatley et al., 2021). However, throughout the COVID-19 305 306 pandemic, the study of anti-SARS-CoV-2 IgA responses have been relatively neglected 307 (Verkerke et al., 2021). The plasma IgA response to SARS-CoV-2 peaks during acute infection 308 but is relatively transient in nature, dominating the acute plasma neutralising response with 309 a 2 phased decay in antibody binding to spike (half-life of 42 days in the first 60 days and >1000 days from 60-160 days post symptom onset) (Sterlin et al., 2021; Wheatley et al., 2021). 310 311 Using our surrogate neutralisation assay, we show that anti-RBD plasma IgA present during early convalescence contributes to the neutralising capacity, in addition to IgG and IgM 312 313 isotypes, for many individuals. As observed by Gasser et al., (2021), we also found decreased 314 neutralisation when IgA was depleted from convalescent plasma, supporting IgA's 315 contribution to SARS-CoV-2 neutralisation. Furthermore, for the first time we show that IgA 316 depletion and IgG depletion also reduces neutralisation for several RBD mutations.

317

We observed IgA-associated and IgA-independent neutralising antibody responses within this convalescent cohort. An IgA-independent neutralising response was observed in 30.3% of individuals with no change in ACE2 binding inhibition when IgA was depleted. While 69.7% of this cohort showed a significant reduction in neutralisation when IgA was depleted, suggesting IgA contributes to neutralization within these individuals. Furthermore, similar to Wang et al., (2021) a subset of convalescent individuals mediated superior neutralisation with IgA when compared to IgG. However, purified IgG mediated higher RBD-ACE2 inhibition

11

compared to purified IgA for most convalescent donors. While IgG and IgA contribute to convalescent plasma neutralisation, depletion of IgG and IgA did not abolish neutralisation in many individuals, supporting the role of IgM in the convalescent plasma neutralising response to SARS-CoV-2 (Gasser et al., 2021; Natarajan, Xu, et al., 2021). Our data further supports the finding that IgA is capable of neutralising SARS-CoV-2 WT, although this response is heterogenous with in this cohort, likely due to heterogeneity in IgA titres against RBD.

331

332 This was confirmed by spiking increasing concentrations of purified IgA back into IgA- plasma, 333 resulting in increased capacity for plasma to mediate SARS-CoV-2 neutralisation. IgA has been 334 widely reported to be broadly cross reactive towards human coronaviruses, particularly in the 335 elderly (Selva et al., 2021a). Therefore, it is also possible that pre-existing IgA+ memory B cells 336 for human coronaviruses may recognise SARS-CoV-2 RBD with higher affinity and undergo somatic hypermutation to create a potent and robust IgA response in some individuals (Wec 337 338 et al., 2020). Another possible explanation for the variability between individuals could be preferential class switching to IgG or IgA due to the cytokine environment and/or host 339 340 genetics. Although, cytokine analysis or sequencing of gamma and alpha genes were not in 341 the scope of this project, the cytokine profiles induced by SARS-CoV-2 vary with disease 342 severity (Ghazavi et al., 2021) and may impact class switching(Cerutti, 2008; Stavnezer, 1996). 343

Intriguingly, we also observed a single individual which showed decreased neutralisation and 344 345 IgM binding to RBDWT when increasing concentrations of purified IgA were spiked back into 346 IgA- depleted plasma. This suggests IgA in rare cases may block RBD-specific IgM antibodies from binding and neutralising SARS-CoV-2. Similarly, HIV-1 vaccine induced IgA antibodies 347 have previously been reported to block binding of IgG to a protective epitope and prevent 348 349 neutralisation and effector functions (Tomaras et al., 2013). However, in most instances anti-350 SARS-CoV-2 convalescent IgA has the capacity to neutralise wild-type SARS-CoV-2 when 351 sufficient titres of IgA are present.

352

As new variants of concern emerge consisting of a constellation of single amino acid substitutions within the RBD, it is important to understand antibody isotype (IgG and IgA) recognition and neutralising capacity to these single site mutations. Single amino acid substitutions can alter the stability and potentially the structure of the RBD, thus may reveal

357 or hide epitopes from different isotypes and/or subclasses of antibodies (Chowdhury et al., 2020; Verma & Subbarao, 2021). For individuals with IgA-skewed neutralisation, we 358 compared the capacity for polyclonal purified convalescent IgA to recognise and neutralise 359 360 single amino acid RBD mutants compared to IgG. We observed minor differences in purified 361 antibody isotype binding to various RBD single mutants, despite the small sample sizes and 362 the polyclonal nature of these convalescent responses. A trend toward preferential IgG 363 binding to many mutants was observed, with significantly increased IgG binding to 5 364 mutations. Interestingly, we observed a trend towards increased IgA binding to a single RBD 365 mutation; G446V, which is predicted to reduce RBD stability and increase ACE2 affinity 366 (Verma & Subbarao, 2021). The Fc portion of the antibody can affect the fine epitope 367 specificity (binding affinity/epitope recognition) of the Fab region which could explain slight variation in IgG and IgA recognition of RBD mutants (Casadevall & Janda, 2012; Ejemel et al., 368 369 2020; Janda et al., 2012; Tudor et al., 2012). Furthermore, increased flexibility of the hinge of 370 IgA1, the predominant subclass of IgA found in blood, may allow for increased accessibility to certain epitopes of Spike and RBD compared to IgG, such as the G446V mutation (Davis et al., 371 372 2020; Ejemel et al., 2020). Overall, our results show that convalescent IgG and IgA broadly recognise similar RBD epitopes with only minor differences in the ability to neutralise RBD 373 374 mutants.

375

376 In addition to antibody neutralisation, Fc effector functions such as phagocytosis, are 377 important for control and clearance of SARS-CoV-2 infection (Butler et al., 2021; Chan et al., 378 2021; Winkler et al., 2021). Similar to previous studies, we show that convalescent plasma 379 can mediate ADP (Butler et al., 2021, W. S. Lee et al., 2021). Interestingly, IgA depletion from convalescent plasma did not impact Fc effector functions by THP-1 monocytes. THP-1 cells 380 381 express relatively low amounts of FcaR, and thus we may not capture the functional potential of IgA the has been alluded to by Butler et al., (2021) who suggested convalescent IgA 382 383 contributes to the functional capacity of convalescent plasma through regression analysis. Importantly, depletion of IgG abolished Fc effector functions in our assays, further reinforcing 384 385 the importance of IgG in the polyfunctional (neutralising and Fc effector function) antibody 386 response of convalescent plasma.

387

388 Overall, we find that convalescent plasma IgA recognises RBDWT and an array of RBD mutants and has the capacity to block ACE2 engagement with RBD in a comparable manner to IgG, 389 390 when sufficient IgA titers are induced. Furthermore, the convalescent IgA neutralising 391 response is highly heterogenous between individuals, with a third of the cohort inducing 392 stronger IgA-mediated inhibition of RBD engagement with ACE2 than IgG, when tested at 393 equivalent concentrations. Dissecting the IgA response in the context of vaccination and to 394 variants of concern is essential to further understand the importance of IgA in a protective 395 polyclonal antibody response.

396

397 Materials and Methods

398 Ethics statement

The study protocols were approved by the University of Melbourne Human Research Ethics Committee (#2056689) and all associated procedures were carried out in accordance with the approved guidelines. All participants provided written informed consent in accordance with the Declaration of Helsinki.

403

404 Human Subjects

405 Participants who had recovered from COVD-19 during the first wave of the pandemic in Melbourne, Australia, March-May 2020, were recruited as previously described (Wheatley et 406 al., 2021). Convalescent subjects were confirmed to have had COVID-19 by returning a 407 408 positive PCR test during early infection or had clear exposure to SARS-CoV-2 and tested positive for SARS-CoV-2 serology (both Spike trimer and RBD) confirming prior exposure as 409 410 previously reported (Juno et al., 2020). Uninfected controls with no COVID-19 symptoms were 411 also recruited during the first wave of COVID-19 and were confirmed as seronegative. Whole blood was collected with sodium heparin. The plasma fraction was then collected and stored 412 at -80°C. Cohort characteristics for convalescent and healthy controls are outlined in Table 413 S1. 414

415

416 Human IgG and IgA ELISA

417 Purified IgG and IgA concentrations were quantified using human anti-IgG kit (cat# 3850-1AD-

418 6 Mabtech) or anti-IgA kit (cat# 3860-1AD-6 Mabtech) respectively as per manufacturer's

419 instructions. Briefly, anti-IgG or IgA capture antibody was coated on Maxisorb 96 well plates (Nunc) overnight at 4^oC. Plates were washed with PBS containing 0.05% Tween20 (PBST) and 420 blocked with 1% BSA/PBST for 2 h. The plates were washed, and purified IgG or IgA antibodies 421 422 were titrated 2-fold from 1:20,000 for a minimum of 4 points. To check for IgG contamination, purified IgA antibodies were tested at 1:1,000 and 1:2,000 dilutions. Similarly purified IgG 423 424 antibodies were tested at 1:1,000 and 1:2,000 to check for IgA contamination. Antibodies and 425 respective standards were incubated for 2h at RT before being washed. The secondary-ALP 426 conjugated antibody was added to each well and incubated at RT for 1 h. The plate was 427 washed, and the substrate p-nitrophenyl-phosphate (pNPP) was added and left to develop 428 (~30mins). The optical density at 405nm was read using Thermo Fisher Multiskan Ascent plate 429 reader. Purified IgA and IgG was confirmed to be free of contamination from the other isotype if their OD was less than the background no antibody OD plus 2 standard deviations. 430

431

432 Antibody purification and depletion

IgA purification and depletion from plasma samples were performed via affinity chromatography using peptide M agarose following manufacturer's instructions (sup. fig. 3a). Briefly, peptide M agarose (Jomar) was added to 1ml filter columns (thermofisher) and washed 3 times with PBS. 300ul of plasma was incubated with peptide M columns for 45 minutes on an orbital at room temperature. Depleted IgA plasma fractions were collected by spinning at 1000g for 1 min after incubation. Purified IgA was eluted with low pH (pH2.8) by IgG Elution Buffer (Thermofisher). Elution was neutralised using Tris M pH 8.0 (Life Sciences).

IgG was purified from 100ul of IgA depleted (IgA-) plasma using 96 well Protein G HP MultiTrap 441 442 (GE Healthcare) following manufacturer's instructions (sup. fig. 3a & b). Purified IgA was also passed through the MultiTrap to remove any IgG contamination. Briefly, IgA- plasma and 443 444 purified IgA was diluted 1:1 in antibody binding buffer and added to the MultiTrap. Samples were incubated for 30 mins at RT while shaking. The plate was centrifuged, IgA and IgG (IgA-445 /IgG-) depleted plasma and purified IgA was collected. The plate was washed with antibody 446 447 binding buffer before elution of IgG with 200ul of elution buffer (GE Healthcare). Purified IgG was collected via centrifugation at 200xg for 2 mins and neutralised to pH 7 using 448 449 neutralisation buffer (GE Healthcare). Elution was performed 3 times and purified IgG, IgA-

450 and IgA-/IgG- plasma was buffer exchanged into PBS and concentrated to original starting451 volume.

452

453 SARS-CoV-2 bead-based multiplex assay

454 The SARS-CoV-2 specific antibody isotypes (IgM, IgG and IgA1) were assessed using a multiplex assay as previously described (Selva et al., 2021). Briefly, bead mixture containing 455 456 700 beads per bead region and diluted plasma or purified antibody, was added to each well 457 in a black clear bottom 384 well plate. Phycoerythrin (PE)-conjugated mouse anti-human pan-IgG and IgA1 (Southern Biotech) (1.3µg/ml) were added to detect SARS-CoV-2 specific 458 459 antibodies. For IgM detection, biotinylated mouse anti-human IgM (mAb MT22; MabTech) was added at 1.3 µg/ml. Following incubation, streptavidin R-Phycoerythrin conjugate (SAPE, 460 461 Invitrogen) at 1 µg/ml was added. The plate was read via the FlexMap 3D and binding of PEdetectors was measured to calculate the median fluorescence intensity (MFI). Background 462 463 was corrected for by subtracting the MFI of BSA-blocked beads for each well. Titrations of 464 pooled convalescent plasma and an anti-SARS-CoV-2 RBD neutralising human IgG1 antibody 465 (SAD-S35, ACRO Biosystems, USA) were included as positive controls and uninfected subject plasma was included as negative controls. A single dilution was used for plasma, depleted 466 plasma and EC₅₀'s were calculated for purified IgG and IgA where appropriate using 467 normalised antibody binding. 468

469

470 RBD-ACE2 binding inhibition multiplex bead-based assay

471 RBD-ACE2 binding inhibition assay was performed as previously described (Lopez et al., 2021). 472 Briefly, an array of SARS-CoV-2 antigens including S1 (Sino Biological), RBD wild-type (WT) (B; 473 wild-type, Wuhan) and 18 RBD single mutants used in figure 3a with 5 additional RBD mutants were included in figure 3b-e, in a bead suspension containing 700 beads per bead region were 474 475 added to each well (20ul), with biotinylated Avitag-ACE2 (kindly provided by Dale Godfrey, Nicholas Gherardin and Samuel Redmond) at a final concentration of 12.5µg/ml per well, and 476 dilutions of plasma or purified antibodies were added to 384-well plates. Biotinylated Avitag-477 478 ACE2 was detected using SAPE at 4µg/ml followed by PE-Biotin amplifier (Thermo Fisher) at 10µg/ml. Plates were washed and acquired on a FlexMap 3D (Luminex). Anti-SARS-CoV-2 RBD 479 480 neutralising human IgG1 antibody (SAD-S35, ACRO Biosystems, USA) was included as a 481 positive control, in addition to COVID-19 negative plasma and buffer only negative controls.

482 The MFI of bound ACE2 was measured after background subtraction of no ACE2 controls.

483 Maximal ACE2 binding MFI was determined by ACE2 only controls. % ACE2 binding inhibition

484 was calculated as 100%–(% ACE2 binding MFI per sample/Maximal ACE2 binding).

485

486 Matching dilutions to account for loss of antibody during depletion process

487 Anti-RBDWT IgM (sup. fig. 3c) and IgG (sup. fig. 3d) binding was also assessed for plasma, IgA-488 and IgA-/IgG- depleted plasma via multiplex. During the depletion process, a loss of 48.88% 489 of IgG (sup. fig. 3c, median MFI=21150, p=0.0160) and 36.95% of IgM (sup. fig. 3d, median MFI=26544, p=0.0002) between medians was observed following the depletion of IgA (IgA-490 491 plasma) and IgG (IgA-/IgG- plasma) respectively compared to plasma (median IgG MFI=41377, 492 median IgM MFI=42101) (sup. fig. 3c-d). To ensure fair comparisons between plasma and 493 depleted plasma fractions, plasma and depleted plasma samples were titrated, and anti-494 RBDWT IgG and IgM binding MFI was determined via multiplex (process outlined in sup. fig. 495 3e). IgA- and IgA-/IgG- depleted plasma dilutions were chosen by matching IgG or IgM MFI 496 respectively to plasma IgG or IgM binding MFI at a dilution of 1:100. IgA- plasma and IgA-/IgG-497 depleted plasma with final dilutions outlined in sup. table 2. These dilutions were used for all 498 multiplex assays. Depleted samples with >30% loss in IgG or IgM following matching of 499 dilutions were excluded from this study (sup. fig. 3b).

500

501 Quality control testing of antibody depleted plasma

502 Successful depletion IgG and IgA was confirmed for matched dilutions via IgG SARS-CoV-2 503 RBDWT multiplex (sup. fig. 3f-k, sup. table 2). This method detected the remaining antigen specific IgG or IgA with high sensitivity which allowed for application of a stringent threshold 504 505 for exclusion of samples with un-successful IgG or IgA depletion. Anti-RBDWT IgG or IgA binding MFI of depleted plasma was compared to full plasma for each subject and the 506 507 percentage reduction in IgG and IgA binding was calculated Sufficient depletion was defined 508 as >70% depletion of IgG or IgA (i.e. >70% reduction in anti-RBDWT IgG MFI compared to 509 plasma IgG MFI) (sup. fig. 3f-k). Plasma, IgA- plasma and IgA-/IgG- depleted plasma samples 510 with <70% IgA or IgG depletion in were all excluded from this study (sup. fig. 3b). Only subjects 511 with all three plasma fractions (plasma, IgA- and IgA-/IgG depleted) were included in final 512 analysis (n=30) (sup. fig. 3b).

513

514 IgA spiking assay

515 Using RBDWT-ACE2 binding inhibition assay and the SARS-CoV-2 multiplex assay, purified IgA 516 was spiked back into IgA- plasma up to 100µg/ml of IgA (12.5, 50 and 100µg/ml) as proof of 517 concept that IgA contributes to ACE2 binding inhibition of convalescent plasma in a dose 518 dependent manor.

- 519
- 520 Fc effector functional assays
- 521 Cell culturing

522 THP-1 monocytes (ATCC) and Ramos cells expressing mOranage2 SARS-CoV-2 spike trimer (Ramos S-orange cells) (W. S. Lee et al., 2021) were cultured in RPMI 1640 with 10% FCS 523 (RF10) under recommended cell culture conditions (37^oC with 5% carbon dioxide (CO₂)). THP-524 525 1 monocytes and Ramos S-orange cells were maintained below a cell density of 0.3 x 10⁴ and 526 1.0 x 10⁴ respectively. Flow cytometry was used to confirm stable expression of FcyRII (CD32), 527 FcyRI (CD64) and FcαR (CD89) on THP-1 monocytes and stable expression of SARS-CoV-2 spike 528 trimer (S-trimer) and expression of mOrange2 for Ramos S-orange cells. Cell viability was 529 determined using trypan blue exclusion and morphology confirmed using light microscopy 530 prior to assay preparation.

531

532 Antibody dependent bead-based phagocytosis assay

Antibody dependent bead-based phagocytosis assay was used as previously described (W. S. 533 534 Lee et al., 2021). Briefly, SARS-CoV-2 spike trimer protein (S-trimer) (supplied by Adam Wheatly, The Peter Doherty Institute) was biotinylated and coupled to 1µm fluorescent 535 NeutrAvidin Fluospheres (beads) (Invitrogen) overnight at 4°C. S-trimer coated beads were 536 washed and diluted 1:100 in 2% BSA/PBS. 10ul of diluted S-trimer coated beads were 537 incubated with plasma diluted 1:100 for 2 hours at 37°C in a 96 well U bottom cell culture 538 539 plate. 10⁴ THP-1 monocytes were added to opsonized beads and incubated for 16 hours under 540 cell culturing conditions. THP-1 monocytes were fixed, and cells were acquired by flow 541 cytometry on a BD LSR Fortessa with a HTS (sup. fig. 6a for gating strategy). The data was 542 analysed using FlowJo 10.7.1 and a phagocytosis score ([% bead positive cells x mean fluorescent intensity]/10³) was calculated as previously described Darrah, Patel et al. (2007). 543

544

545 THP-1 and Ramos S-orange cell association assay

A THP-1 and Ramos S-orange cell association was used as previously described (W. S. Lee et 546 al., 2021). Briefly, THP-1 monocytes were stained with CellTrace[™] Violet (CTV) (Life 547 Technologies) as per manufacturer's instructions. Concurrently, 10⁴ Ramos S-orange cells 548 549 were added to each well in a 96-well V bottom cell culture plate. Plasma was diluted to 1:900 550 with the Ramos S-orange cells and incubated for 30 minutes under cell culture conditions. 551 Opsonised Ramos S-orange cells were washed by centrifugation and 10⁴ of CTV stained THP-1 monocytes were added for a final 1:1 ratio of THP-1 monocytes to Ramos S-orange cells. 552 Opsonised Ramos S-orange cells and THP-1 monocytes were incubated for 1 hour under cell 553 554 culture conditions before fixation. Cells were acquired by flow cytometry using the BD LSR 555 Fortessa with a high-throughput sampler attachment (HTS) and the data was analysed using 556 FlowJo 10.7.1 (sup. fig. 6b for gating strategy). The percentage of Ramos S-orange cells 557 associated with THP-1 monocytes (% association) was extracted.

558

559 Data normalisation

For purified antibody binding to the RBD single mutants of subjects with IgA neutralisation 560 561 (n=13), antibody MFI values were normalised to the maximum antibody binding (100%) (IgG 562 and IgA) to each variant to account for differences in coupling efficiency for the RBD mutants. 563 The normalised purified antibody binding was used to calculate EC_{50} 's for purified IgG and IgA. 564 EC_{50} 's >400 were set to the threshold of 400.

565

566 Data analysis

567 Traditional statistical analyses were performed with Graphpad Prism 9. See figure ledgends 568 for details. Partial Least Squares Regression Analyses were conducted to determine multivariate relationships between immune features and continuous variables (e.g. ACE2 569 binding inhibition) using Matlab with the statistics and machine learning toolbox 570 571 (Mathsworks) and PLS_Toolbox (Eigenvector).

572

573 Acknowledgments

- This study was supported by the Medical Research Future Fund (MRFF) (W.-H.T., 574 D.I.G., A.W.C., S.J.K., A.K.W. and J.A.J), Emergent Ventures Fast Grant (A.W.C.) 575 and the Paul Ramsay Foundation (D.I.G., S.J.K., A.K.W and A.W.C). A.K.W., J.A.J, 576 577 D.I.G., W.-H.T., S.J.K., and A.W.C are supported by NHMRC fellowships. W-H.T. is a Howard Hughes Medical Institute–Wellcome Trust International Research Scholar 578 (208693/Z/17/Z). N.A.G. is supported by an ARC DECRA fellowship. 579
- 580
- **Figure Legends** 581
- Figure 1. Convalescent plasma induced robust anti-SARS-CoV-2 RBDWT antibody isotypes 582 583 levels that inhibit ACE2 from binding RBDWT
- 584 Convalescent (n-41) (blue) and uninfected control (n=26) (grey) plasma (final dilution 1:100) was assessed for IgM (a), IgG (b) and IgA (c) antibody binding to SARS-CoV-2 RBDWT via 585 multiplex. A positive threshold (grey dotted line) was defined as the 75th percentile of 586 antibody binding (MFI) for uninfected control plasma to respective antigens. (d) RBDWT ACE2 587 binding inhibition (%) of convalescent (blue) and uninfected control (grey) plasma (diluted 588 1:100). A positive threshold (grey dotted line) was defined as >20% ACE2 binding inhibition. 589 590 (e) Pie chart outlining the percentage of subjects seropositive for anti-RBDWT antibody 591 isotypes (IgM-IgG+IgA+ (green), IgM+IgG+IgA+ (blue), IgM+IgG+IgA- (yellow)) in the inner ring 592 and the percentage of each seropositive subset with ACE2 binding inhibition in the outer red 593 ring. Partial Least Squares Regression (PLSR) were conducted to determine the multivariate 594 relationship between anti-RBD-specific isotype antibodies (IgG, IgA, and IgM) and % RBDWT-ACE2 binding inhibition (% ACE2 binding inhibition illustrated as a colour gradient legend on 595 596 the right- yellow-strongest to dark blue- weakest). PLSR Scores (f) and loadings plot (g). 597 Percent variance for each latent variable (LV) in parentheses.
- 598

599 Figure 2. IgA from convalescent plasma induces variable levels of % RBD-ACE2 binding 600 inhibition.

SARS-CoV-2 RBDWT ACE2 binding inhibition (%) of (a) convalescent plasma (diluted 1:200; 601 602 blue) and matched dilutions of IgA depleted (IgA-; yellow) and IgA plus IgG depleted (IgA-/IgG-; purple) (n=30) plasma fractions. Comparisons between plasma and depleted fractions was 603 conducted using Friedman with Dunn's multiple comparison test. (sup. Fig. 3 describes 604 605 inclusion/exclusion criteria for successful antibody depletion); Comparison of matched

606 purified IgG (green) and IgA (blue) RBDWT ACE2 binding inhibition tested at 100µg/ml total purified antibody separated as individuals where (b) purified IgG or (c) purified IgA mediated 607 608 enhanced ACE2 binding inhibition. (d) Correlation (non-parametric Spearman test) between 609 RBDWT-ACE2 binding inhibition (%) and anti-RBDWT antibody IgG and IgA isotype binding 610 (MFI) tested at 100µg/ml total antibody. (e) RBDWT IgA binding (MFI) and (f) ACE2 binding inhibition (%) were assessed as increasing concentrations (yellow, 0, 12.5, 50 and 100µg/ml 611 612 total antibody) of purified COVID+ IgA was spiked back into IgA depleted plasma (n=3). While 613 (g) samples where IgA depletion resulted in an increase in RBDWT ACE2 binding inhibition (h) 614 anti-RBDWT antibody IgG, IgA and IgM isotype binding (MFI) and (i) ACE2 binding inhibition (%) were assessed as increasing concentrations of purified IgA were spiked back into 615 616 respective IgA- depleted plasma for this individual.

617

Figure 3. Similar antibody binding and ACE2 binding inhibition of convalescent purified IgA to RBD single mutants compared to IgG

(a) Heatmap of the mean ACE2 binding inhibition (%) for RBDWT and 18 RBD single mutants 620 621 of matched complete plasma, IgA- depleted , and IgA-/IgG- depleted plasma (n=30). Purified 622 IgA (blue) and IgG (green) (b) fold change in antibody EC₅₀ binding relative to RBDWT for 23 623 different RBD single mutants of subjects (n=13) (c) Fold change in RBD-ACE2 binding inhibition 624 relative to RBDWT for 23 different RBD single mutants of subjects for the same samples (n=13). Statistical analyses were performed with the Paired t test adjusting for multiple 625 comparisons using the Holm-Šídák method (*=p<0.05, **=p<0.01). The median fold change 626 627 in (d) antibody EC_{50} binding and (e) % RBD-ACE2 binding inhibition relative to RBDWT for each 628 RBD mutant is summarized as heatmaps.

629

Figure 4. Depletion of IgG but not IgA reduces the Fc functional capacity of convalescentplasma

(a) Antibody dependent phagocytosis (ADP) of S-conjugated beads for a subset of
convalescent subject plasma (blue) (n=18) and uninfected control plasma (grey) (n=12)
(diluted 1:900). (b) Comparison of ADP of S-conjugated beads from matched convalescent
subject plasma (blue), IgA depleted plasma (IgA-; yellow) and IgA and IgG depleted plasma
(IgA-/IgG-; purple) (n=18). (c) Fcy Receptor (FcyR) dependent association of THP-1 cells with
Ramos S-orange cells mediated by convalescent plasma (blue) and uninfected control plasma

(grey) (diluted 1:100). (d) FcyR dependent association of THP-1 cells with Ramos S-orange
cells from matched convalescent subject plasma (blue), IgA depleted plasma (IgA-; yellow)
and IgA and IgG depleted plasma (IgA-/IgG-; purple) (n=18). Grey dotted lines denote the
negative threshold for cell association (<2%) and ADP (3 X 10³) calculated as the mean
response of negative subject plasma plus 2 standard deviations. Statistical analyses were
performed with the Kruskal-Wallis test followed by Dunn's multiple comparisons test.

645

References 646

- 647
- 648 Asokan, M., Diasb, J., Liu, C., Maximovaa, A., Ernste, K., Pegu, A., McKee, K., Shi, W., Chen, 649 X., Almasri, C., Promsote, W., Ambrozak, D. R., Gama, L., Hu, J., Douek, D. C., Todd, J. P., 650 Lifson, J. D., Fourati, S., Sekaly, R. P., ... Koup, R. A. (2020). Fc-mediated effector 651 function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. 652 Proceedings of the National Academy of Sciences of the United States of America, 117(31), 18754-18763. https://doi.org/10.1073/PNAS.2008236117/-653 /DCSUPPLEMENTAL 654 655 Blutt, S. E., Miller, A. D., Salmon, S. L., Metzger, D. W., & Conner, M. E. (2012). IgA is Important for Clearance and Critical for Protection from Rotavirus Infection. Mucosal 656 657 Immunology, 5(6), 712. https://doi.org/10.1038/MI.2012.51 658 Brown, E. P., Licht, A. F., Dugast, A. S., Choi, I., Bailey-Kellogg, C., Alter, G., & Ackerman, M. 659 E. (2012). High-throughput, multiplexed IgG subclassing of antigen-specific antibodies 660 from clinical samples. Journal of Immunological Methods, 386(1-2), 117-123. 661 https://doi.org/10.1016/J.JIM.2012.09.007 662 Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., 663 Lee, J., Wieland-Alter, W., Connor, R. I., Wright, P. F., & Ackerman, M. E. (2021). Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among 664 SARS-CoV-2 Convalescent Individuals. Frontiers in Immunology, 11, 3797. 665 666 https://doi.org/10.3389/FIMMU.2020.618685/BIBTEX 667 Casadevall, A., & Janda, A. (2012). Immunoglobulin isotype influences affinity and specificity. 668 Proceedings of the National Academy of Sciences, 109(31), 12272–12273. https://doi.org/10.1073/PNAS.1209750109 669 670 Cerutti, A. (2008). The regulation of IgA class switching. Nature Reviews Immunology 2008 671 8:6, 8(6), 421–434. https://doi.org/10.1038/nri2322 Chan, C. E. Z., Seah, S. G. K., Chye, D. H., Massey, S., Torres, M., Lim, A. P. C., Wong, S. K. K., 672 Neo, J. J. Y., Wong, P. S., Lim, J. H., Loh, G. S. L., Wang, D., Boyd-Kirkup, J. D., Guan, S., 673 674 Thakkar, D., Teo, G. H., Purushotorman, K., Hutchinson, P. E., Young, B. E., ... Hanson, B. 675 J. (2021). The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing 676 antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for 677 the optimal therapeutic efficacy of the antibody. PLOS ONE, 16(6), e0253487. 678 https://doi.org/10.1371/JOURNAL.PONE.0253487 Choi, J. Y., & Smith, D. M. (2021). SARS-CoV-2 Variants of Concern. Yonsei Medical Journal, 679 680 62(11), 961. https://doi.org/10.3349/YMJ.2021.62.11.961 681 Chowdhury, R., Boorla, V. S., & Maranas, C. D. (2020). Computational biophysical 682 characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and 683 implications for infectivity. Computational and Structural Biotechnology Journal, 18, 684 2573-2582. https://doi.org/10.1016/J.CSBJ.2020.09.019 685 Collier, A. Y., Yu, J., McMahan, K., Liu, J., Chandrashekar, A., Maron, J. S., Atyeo, C., Martinez, 686 D. R., Ansel, J. L., Aguayo, R., Rowe, M., Jacob-Dolan, C., Sellers, D., Barrett, J., Ahmad, K., Anioke, T., VanWyk, H., Gardner, S., Powers, O., ... Barouch, D. H. (2021). Differential 687 688 Kinetics of Immune Responses Elicited by Covid-19 Vaccines. New England Journal of Medicine, 385(21), 2010–2012. 689 690 https://doi.org/10.1056/NEJMC2115596/SUPPL FILE/NEJMC2115596 DISCLOSURES.P 691 DF

- 692 Davis, S. K., Selva, K. J., Kent, S. J., & Chung, A. W. (2020). Serum IgA Fc effector functions in 693 infectious disease and cancer. Immunology and Cell Biology, 98(4), 276–286. https://doi.org/10.1111/IMCB.12306 694
- 695 Devarasetti, P. K., Rajasekhar, L., Baisya, R., Sreejitha, K. S., & Vardhan, Y. K. (2021). A review 696 of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. 697 Immunologic Research 2021 69:1, 69(1), 18–25. https://doi.org/10.1007/S12026-020-698 09169-X
- 699 Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, 700 A., Planchais, C., Buchrieser, J., Robinot, R., Ungeheuer, M. N., Mouquet, H., Charneau, 701 P., White, M., Lévy, Y., Hoen, B., Fontanet, A., Schwartz, O., & Bruel, T. (2021).
- 702 Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. 703 Cell Reports Medicine, 2(5), 100275. https://doi.org/10.1016/J.XCRM.2021.100275
- 704 Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., 705 Hallett, S. R., Pickering, S., Charalampous, T., Alcolea-Medina, A., Huettner, I., Jimenez-706 Guardeño, J. M., Acors, S., Almeida, N., Cox, D., Dickenson, R. E., Galao, R. P., Kouphou, 707 N., ... Doores, K. J. (2021). Neutralizing antibody activity in convalescent sera from 708 infection in humans with SARS-CoV-2 and variants of concern. *Nature Microbiology*
- 709 2021 6:11, 6(11), 1433-1442. https://doi.org/10.1038/s41564-021-00974-0
- 710 Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Tree, J. A., Wallace, A., Amcheslavsky, A., Kurt 711 Yilmaz, N., Buttigieg, K. R., Elmore, M. J., Godwin, K., Coombes, N., Toomey, J. R., 712 Schneider, R., Ramchetty, A. S., Close, B. J., Chen, D.-Y., Conway, H. L., Saeed, M., ... 713 Wang, Y. (2020). A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 714 spike-ACE2 interaction. Nature Communications 2020 11:1, 11(1), 1-9. 715 https://doi.org/10.1038/s41467-020-18058-8
- 716 Falsey, A. R., Frenck, R. W., Walsh, E. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., 717 Bailey, R., Swanson, K. A., Xu, X., Koury, K., Kalina, W., Cooper, D., Zou, J., Xie, X., Xia, 718 H., Türeci, Ö., Lagkadinou, E., Tompkins, K. R., ... Gruber, W. C. (2021). SARS-CoV-2 719 Neutralization with BNT162b2 Vaccine Dose 3. New England Journal of Medicine,
- 720 385(17), 1627-1629.
- https://doi.org/10.1056/NEJMC2113468/SUPPL_FILE/NEJMC2113468_DISCLOSURES.P 721 722 DF
- 723 Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser, 724 B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., Charles, R. 725 C., Dighe, A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., Iafrate, A. J., & 726 Balazs, A. B. (2021). COVID-19-neutralizing antibodies predict disease severity and
- 727 survival. Cell, 184(2), 476-488.e11. https://doi.org/10.1016/J.CELL.2020.12.015
- 728 Gasser, R., Cloutier, M., Prévost, J., Fink, C., Ducas, É., Ding, S., Dussault, N., Landry, P., 729 Tremblay, T., Laforce-Lavoie, A., Lewin, A., Beaudoin-Bussières, G., Laumaea, A., 730 Medjahed, H., Larochelle, C., Richard, J., Dekaban, G. A., Dikeakos, J. D., Bazin, R., & 731 Finzi, A. (2021). Major role of IgM in the neutralizing activity of convalescent plasma 732 against SARS-CoV-2. Cell Reports, 34(9), 108790.
- https://doi.org/10.1016/J.CELREP.2021.108790 733
- 734 Ghazavi, A., Ganji, A., Keshavarzian, N., Rabiemajd, S., & Mosayebi, G. (2021). Cytokine 735 profile and disease severity in patients with COVID-19. Cytokine, 137, 155323.
- 736 https://doi.org/10.1016/J.CYTO.2020.155323
- 737 Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., 738 Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium,

739 Peacock, S. J., & Robertson, D. L. (2021). SARS-CoV-2 variants, spike mutations and 740 immune escape. Nature Reviews. Microbiology, 1–16. https://doi.org/10.1038/s41579-741 021-00573-0 742 Janda, A., Eryilmaz, E., Nakouzi, A., Cowburn, D., & Casadevall, A. (2012). Variable Region 743 Identical Immunoglobulins Differing in Isotype Express Different Paratopes *. Journal of 744 Biological Chemistry, 287(42), 35409–35417. 745 https://doi.org/10.1074/JBC.M112.404483 746 Juno, J. A., Tan, H.-X., Lee, W. S., Reynaldi, A., Kelly, H. G., Wragg, K., Esterbauer, R., Kent, H. 747 E., Batten, C. J., Mordant, F. L., Gherardin, N. A., Pymm, P., Dietrich, M. H., Scott, N. E., 748 Tham, W.-H., Godfrey, D. I., Subbarao, K., Davenport, M. P., Kent, S. J., & Wheatley, A. 749 K. (2020). Humoral and circulating follicular helper T cell responses in recovered 750 patients with COVID-19. Nature Medicine 2020 26:9, 26(9), 1428-1434. 751 https://doi.org/10.1038/s41591-020-0995-0 752 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, 753 K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are 754 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. 755 Nature Medicine 2021 27:7, 27(7), 1205–1211. https://doi.org/10.1038/s41591-021-756 01377-8 757 Klingler, J., Weiss, S., Itri, V., Liu, X., Oguntuyo, K. Y., Stevens, C., Ikegame, S., Hung, C.-T., 758 Envindah-Asonye, G., Amanat, F., Baine, I., Arinsburg, S., Bandres, J. C., Kojic, E. M., 759 Stoever, J., Jurczyszak, D., Bermudez-Gonzalez, M., Simon, V., Nádas, A., ... Hioe, C. E. 760 (2020). Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. MedRxiv : 761 The Preprint Server for Health Sciences. https://doi.org/10.1101/2020.08.18.20177303 762 Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., 763 Haycroft, E. R., Tan, H. X., Juno, J. A., Wheatley, A. K., Hogarth, P. M., Cromer, D., 764 Davenport, M. P., Chung, A. W., & Kent, S. J. (2021). Decay of Fc-dependent antibody 765 functions after mild to moderate COVID-19. Cell Reports Medicine, 2(6), 100296. https://doi.org/10.1016/J.XCRM.2021.100296 766 Lee, W. T., Girardin, R. C., Dupuis, A. P., Kulas, K. E., Payne, A. F., Wong, S. J., Arinsburg, S., 767 768 Nguyen, F. T., Mendu, D. R., Firpo-Betancourt, A., Jhang, J., Wajnberg, A., Krammer, F., 769 Cordon-Cardo, C., Amler, S., Montecalvo, M., Hutton, B., Taylor, J., & McDonough, K. A. 770 (2021). Neutralizing Antibody Responses in COVID-19 Convalescent Sera. The Journal of 771 Infectious Diseases, 223(1), 47–55. https://doi.org/10.1093/INFDIS/JIAA673 Liu, X., Wang, J., Xu, X., Liao, G., Chen, Y., & Hu, C.-H. (2020). Patterns of IgG and IgM 772 773 antibody response in COVID-19 patients. 774 Https://Doi.Org/10.1080/22221751.2020.1773324, 9(1), 1269-1274. 775 https://doi.org/10.1080/22221751.2020.1773324 776 Lopez, E., Haycroft, E. R., Adair, A., Mordant, F. L., O'Neill, M. T., Pymm, P., Redmond, S. J., 777 Lee, W. S., Gherardin, N. A., Wheatley, A. K., Juno, J. A., Selva, K. J., Davis, S. K., Grimley, 778 S. L., Harty, L., Purcell, D. F. J., Subbarao, K., Godfrey, D. I., Kent, S. J., ... Chung, A. W. 779 (2021). Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. https://doi.org/10.1172/JCI.INSIGHT.150012 780 781 Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., 782 Mandelboim, M., Doolman, R., Amit, S., Mendelson, E., Ziv, A., Huppert, A., Rubin, C., Freedman, L., & Kreiss, Y. (2021). BNT162b2 COVID-19 vaccine and correlates of 783 784 humoral immune responses and dynamics: a prospective, single-centre, longitudinal

785	cohort study in health-care workers. <i>The Lancet. Respiratory Medicine, 9</i> (9), 999.
786	https://doi.org/10.1016/S2213-2600(21)00220-4
787	Maeda, K., Higashi-Kuwata, N., Kinoshita, N., Kutsuna, S., Tsuchiya, K., Hattori, S., Matsuda,
788	K., Takamatsu, Y., Gatanaga, H., Oka, S., Sugiyama, H., Ohmagari, N., & Mitsuya, H.
789	(2021). Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.
790	Scientific Reports 2021 11:1, 11(1), 1–12. https://doi.org/10.1038/s41598-021-84733-5
791	Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K.,
792	Wieland-Alter, W., Connor, R. I., Wright, P. F., Benner, S. E., Bonny, T. S., Laeyendecker,
793	O., Sullivan, D., Shoham, S., Quinn, T. C., Larman, H. B., Casadevall, A., Pekosz, A.,
794	Ackerman, M. E. (2021a). Markers of polyfunctional sars-cov-2 antibodies in
795	convalescent plasma. <i>MBio, 12</i> (2). https://doi.org/10.1128/MBIO.00765-
796	21/SUPPL_FILE/MBIO.00765-21-ST003.PDF
797	Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K.,
798	Wieland-Alter, W., Connor, R. I., Wright, P. F., Benner, S. E., Bonny, T. S., Laeyendecker,
799	O., Sullivan, D., Shoham, S., Quinn, T. C., Larman, H. B., Casadevall, A., Pekosz, A.,
800	Ackerman, M. E. (2021b). Markers of polyfunctional sars-cov-2 antibodies in
801	convalescent plasma. <i>MBio</i> , 12(2). https://doi.org/10.1128/MBIO.00765-21
802	Natarajan, H., Xu, S., Crowley, A. R., Butler, S. E., Weiner, J. A., Bloch, E. M., Littlefield, K.,
803	Benner, S. E., Shrestha, R., Ajayi, O., Wieland-Alter, W., Sullivan, D., Shoham, S., Quinn,
804	T. C., Casadevall, A., Pekosz, A., Redd, A. D., Tobian, A. A. R., Connor, R. I., Ackerman,
805	M. E. (2021). Antibody Attributes that Predict the Neutralization and Effector Function
806	of Polyclonal Responses to SARS-CoV-2. <i>MedRxiv</i> .
807	https://doi.org/10.1101/2021.08.06.21261710
808	Plotkin, S. A. (2010). Correlates of Protection Induced by Vaccination. Clinical and Vaccine
809	Immunology, 17(7), 1055–1065. https://doi.org/10.1128/CVI.00131-10
810	Rössler, A., Riepler, L., Bante, D., Laer, D. von, & Kimpel, J. (2021). SARS-CoV-2 B.1.1.529
811	variant (Omicron) evades neutralization by sera from vaccinated and convalescent
812	individuals. <i>MedRxiv</i> , 2021.12.08.21267491.
813	https://doi.org/10.1101/2021.12.08.21267491
814	Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021). Immunological mechanisms of
815	vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology
816	<i>2021 21:8, 21</i> (8), 475–484. https://doi.org/10.1038/s41577-021-00578-z
817	Selva, K. J., van de Sandt, C. E., Lemke, M. M., Lee, C. Y., Shoffner, S. K., Chua, B. Y., Davis, S.
818	K., Nguyen, T. H. O., Rowntree, L. C., Hensen, L., Koutsakos, M., Wong, C. Y., Mordant,
819	F., Jackson, D. C., Flanagan, K. L., Crowe, J., Tosif, S., Neeland, M. R., Sutton, P.,
820	Chung, A. W. (2021a). Systems serology detects functionally distinct coronavirus
821	antibody features in children and elderly. Nature Communications 2021 12:1, 12(1), 1–
822	14. https://doi.org/10.1038/s41467-021-22236-7
823	Stavnezer, J. (1996). Immunoglobulin class switching. Current Opinion in Immunology, 8(2),
824	199–205. https://doi.org/10.1016/S0952-7915(96)80058-6
825	Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J.,
826	Devilliers, H., Ghillani, P., Gunn, C., Hockett, R., Mudumba, S., Guihot, A., Luyt, CE.,
827	Mayaux, J., Beurton, A., Fourati, S., Bruel, T., Gorochov, G. (2021). IgA dominates the
828	early neutralizing antibody response to SARS-CoV-2. In Sci. Transl. Med (Vol. 13).
829	http://stm.sciencemag.org/
830	Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard,

831 N., Laumaea, A., Vézina, D., Prévost, J., Anand, S. P., Bourassa, C., Gendron-Lepage, G.,

832 Medjahed, H., Goyette, G., Niessl, J., Tastet, O., Gokool, L., Morrisseau, C., ... Finzi, A. 833 (2021). A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody 834 effector functions and T cell responses. Cell Host and Microbe. 835 https://doi.org/10.1016/j.chom.2021.06.001 836 Tomaras, G. D., Ferrari, G., Shen, X., Alam, S. M., Liao, H. X., Pollara, J., Bonsignori, M., 837 Moody, M. A., Fong, Y., Chen, X., Poling, B., Nicholson, C. O., Zhang, R., Lu, X., Parks, R., 838 Kaewkungwal, J., Nitayaphan, S., Pitisuttithum, P., Rerks-Ngarm, S., ... Haynes, B. F. 839 (2013). Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of 840 841 Sciences of the United States of America, 110(22), 9019–9024. 842 https://doi.org/10.1073/PNAS.1301456110/-/DCSUPPLEMENTAL Tudor, D., Yu, H., Maupetit, J., Drillet, A. S., Bouceba, T., Schwartz-Cornil, I., Lopalco, L., 843 844 Tuffery, P., & Bomsel, M. (2012). Isotype modulates epitope specificity, affinity, and 845 antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proceedings 846 of the National Academy of Sciences of the United States of America, 109(31), 12680-847 12685. https://doi.org/10.1073/PNAS.1200024109/-/DCSUPPLEMENTAL 848 Ullah, I., Prévost, J., Ladinsky, M. S., Stone, H., Lu, M., Anand, S. P., Beaudoin-Bussières, G., 849 Symmes, K., Benlarbi, M., Ding, S., Gasser, R., Fink, C., Chen, Y., Tauzin, A., Goyette, G., 850 Bourassa, C., Medjahed, H., Mack, M., Chung, K., ... Uchil, P. D. (2021). Live imaging of 851 SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 54(9), 2143. 852 853 https://doi.org/10.1016/J.IMMUNI.2021.08.015 854 Verkerke, H., Saeedi, B. J., Boyer, D., Allen, J. W., Owens, J., Shin, S., Horwath, M., Patel, K., 855 Paul, A., Wu, S., Wang, J., Ho, A., Maier, C. L., Zerra, P. E., Chonat, S., Arthur, C. M., 856 Roback, J. D., Neish, A. S., Lough, C., ... Stowell, S. R. (2021). Are We Forgetting About 857 IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma. Transfusion, 858 61(6), 1740. https://doi.org/10.1111/TRF.16435 Verma, J., & Subbarao, N. (2021). Insilico study on the effect of SARS-CoV-2 RBD hotspot 859 mutants' interaction with ACE2 to understand the binding affinity and stability. 860 Virology, 561, 107-116. https://doi.org/10.1016/J.VIROL.2021.06.009 861 Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., 862 863 Hoffmann, H. H., Oliveira, T. Y., Oren, D. A., Ramos, V., Nogueira, L., Michailidis, E., Robbiani, D. F., Gazumyan, A., Rice, C. M., Hatziioannou, T., Bieniasz, P. D., Caskey, M., 864 865 & Nussenzweig, M. C. (2021). Enhanced SARS-CoV-2 neutralization by dimeric IgA. 866 Science Translational Medicine, 13(577), 1555. https://doi.org/10.1126/scitranslmed.abf1555 867 868 Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. 869 K., Eugenia Dieterle, M., Lilov, A., Huang, D., Tse, L. v., Johnson, N. v., Hsieh, C. L., 870 Wang, N., Nett, J. H., Champney, E., Burnina, I., Brown, M., Lin, S., ... Walker, L. M. 871 (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. 872 Science, 369(6504), 731-736. https://doi.org/10.1126/SCIENCE.ABC7424/SUPPL FILE/PAP.PDF 873 874 Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H. X., Lee, W. S., Wragg, 875 K. M., Kelly, H. G., Esterbauer, R., Davis, S. K., Kent, H. E., Mordant, F. L., Schlub, T. E., 876 Gordon, D. L., Khoury, D. S., Subbarao, K., Cromer, D., Gordon, T. P., ... Kent, S. J. 877 (2021). Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. 878 Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-21444-5

- 879 Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H.,
- 880 Huang, Y., Allen, J. D., Case, J. B., Sutton, R. E., Carnahan, R. H., Darling, T. L., Boon, A. C.
- 881 M., Mack, M., Head, R. D., Ross, T. M., Crowe, J. E., & Diamond, M. S. (2021). Human
- neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for 882 883 optimal therapeutic protection. Cell, 184(7), 1804-1820.e16.
- 884 https://doi.org/10.1016/j.cell.2021.02.026
- 885 Wrapp, D., Wang, N., Corbett, K., & ... J. G. (2020). Cryo-EM structure of the 2019-nCoV 886 spike in the prefusion conformation. *Science.Sciencemag.Org*.
- 887 https://science.sciencemag.org/content/367/6483/1260.abstract
- Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, 888
- J., Hauser, B. M., Caradonna, T., Schmidt, A. G., Cai, Y., Streeck, H., Ryan, E. T., Barouch, 889
- D. H., Charles, R. C., Lauffenburger, D. A., & Alter, G. (2020). Compromised Humoral 890
- 891 Functional Evolution Tracks with SARS-CoV-2 Mortality. *Cell*, 183(6), 1508-1519.e12.
- 892 https://doi.org/10.1016/J.CELL.2020.10.052
- 893







а



